The Centers for Disease Control and Prevention (CDC) intends to award a sole source contract to Micron Biomedical Incorporated for the manufacturing of a dissolving microneedle patch to administer a live attenuated rotavirus vaccine. The contract will be for a firm fixed price, and the period of performance is expected to be from April 15, 2026, to April 14, 2028. The CDC is seeking capability statements from interested sources, which should include management and technical data, as well as cost information. The capability statements should demonstrate the source's ability to provide the required services and warranties. • The contract is for the manufacturing of a dissolving microneedle patch to administer a live attenuated rotavirus vaccine. • The period of performance is from April 15, 2026, to April 14, 2028. • The contract will be a firm fixed price contract. • Capability statements should include management and technical data, as well as cost information. • The CDC is seeking capability statements from interested sources to determine whether to conduct a competitive procurement or to proceed with a sole source contract.